What are the evidence‑based treatment options for adult sleep disorders, including insomnia, obstructive sleep apnea, restless legs syndrome, and circadian‑rhythm disorders?

Evidence-Based Treatment for Adult Sleep Disorders

Cognitive behavioral therapy for insomnia (CBT-I) is the mandatory first-line treatment for chronic insomnia in all adults, with pharmacotherapy reserved only for short-term use after CBT-I fails. 1

Chronic Insomnia Disorder

First-Line Treatment: CBT-I

CBT-I combines cognitive therapy, behavioral interventions (sleep restriction and stimulus control), and sleep hygiene education. It can be delivered through multiple formats: individual therapy, group sessions, telephone/web-based modules, or self-help books—all showing effectiveness 1, 2.

Why CBT-I comes first:

• Moderate-quality evidence shows improved remission rates, treatment response, reduced Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) scores
• Reduces sleep onset latency and wake after sleep onset
• Improves sleep efficiency and quality in both general and older adult populations
• Benefits are durable long-term without additional interventions
• Minimal harms (temporary early-treatment fatigue/irritability that resolve) 1, 2

Critical caveat: Sleep restriction therapy within CBT-I is contraindicated in heavy machinery operators, drivers, and patients with poorly controlled seizures or predisposition to mania/hypomania 2.

Second-Line: Pharmacotherapy (Only After CBT-I Failure)

Use shared decision-making to discuss benefits, harms, and costs before initiating any medication. 1

FDA-approved options with evidence:

• Suvorexant (orexin antagonist): Moderate-quality evidence for improved treatment response and sleep outcomes; emerging dual orexin receptor antagonists show promise with favorable safety profiles 1, 3, 4, 5
• Eszopiclone and zolpidem (nonbenzodiazepine hypnotics): Low-quality evidence for improved global and sleep outcomes in general population; eszopiclone shows benefit in older adults 1
• Doxepin (low-dose antidepressant): Moderate-quality evidence for improved ISI scores and sleep outcomes in older adults 1, 5
• Ramelteon (melatonin receptor agonist): Low-quality evidence; decreased sleep onset latency in older adults but no significant difference vs. placebo in general population 1

Medications with insufficient evidence:

• Melatonin: Insufficient evidence in both general and older adult populations 1, 6
• Benzodiazepines: Insufficient evidence (few studies met inclusion criteria) 1
• Trazodone and diphenhydramine: Not adequately studied despite common use 1

Critical Safety Warnings

All hypnotic drugs carry serious risks:

• Observational studies link them to dementia, fractures, serious injury, and motor vehicle accidents 1
• FDA warnings include daytime impairment, "sleep driving," behavioral abnormalities, and worsening depression 1
• FDA recommends lower doses in women, older adults, and debilitated patients 1
• FDA approval is for short-term use only (4-5 weeks)—patients must not continue extended use 1
• Evidence is insufficient for long-term safety and efficacy 1

Brief Behavioral Therapy for Insomnia (BBT-I)

The American Academy of Sleep Medicine suggests multicomponent brief therapies (1-4 sessions emphasizing behavioral components) as an alternative when full CBT-I is unavailable, though CBT-I has more robust evidence 2, 6.

Obstructive Sleep Apnea (OSA)

Continuous positive airway pressure (CPAP) remains the standard of care for OSA, though adherence challenges persist 3, 4. The 2019 VA/DoD guidelines provide comprehensive OSA management algorithms, emphasizing timely diagnosis and PAP therapy as primary treatment, with alternative options for patients who don't benefit from CPAP 6.

Restless Legs Syndrome (RLS)

Iron Supplementation

In adults with RLS, use ferrous sulfate when appropriate iron parameters indicate deficiency (check ferritin and transferrin saturation) 7. In RLS patients with end-stage renal disease (ESRD), use IV iron sucrose when ferritin <200 ng/mL and transferrin saturation <20% 7.

Pharmacotherapy Considerations

Critical warning about dopamine agonists: While historically used, these carry significant augmentation risk (worsening of symptoms with long-term use). Alternatives should be considered more often 4, 8.

• Gabapentin: Suggested for RLS in ESRD patients 7
• Levodopa and rotigotine: Suggested against standard use in ESRD due to augmentation risk with long-term use 7
• Avoid valerian (conditional recommendation against use) 7

Pediatric RLS

Use ferrous sulfate in children with RLS and appropriate iron status 7.

Circadian Rhythm Disorders

Evidence for melatonin in circadian disorders shows approximately 7-minute decrease in sleep latency and 8-minute increase in total sleep time, but clinical significance is unclear 6. The VA/DoD guidelines note highly variable treatment durations and doses across studies, with meta-regression suggesting longer durations and higher doses may show greater effects 6.

Special Populations

Older Adults

• More likely to report sleep maintenance problems (wake after sleep onset) than sleep onset difficulties 1
• Increased sensitivity to peak drug effects and reduced clearance of sedative-hypnotics 9
• Combination therapy (behavioral + pharmacologic) may be more efficacious than either alone in older adults, though behavioral treatment provides better sustained long-term benefit 9
• Normal aging involves reduced slow-wave and REM sleep, decreased efficiency, and increased fragmentation—distinguish this from pathological disorders 3

Comorbid Conditions

Insomnia in older adults is most often comorbid with medical and psychiatric illness, complicated by polypharmacy. Successful sleep management may improve quality of life, daytime functioning, reduce falls, and improve comorbidities 9.

Key Pitfalls to Avoid

1. Starting medications before trying CBT-I—this violates evidence-based guidelines 1
2. Long-term hypnotic use—FDA approval is short-term only; extended use lacks safety data 1
3. Using dopamine agonists as first-line for RLS—augmentation risk makes alternatives preferable 4, 8
4. Ignoring iron status in RLS—check and correct before other interventions 7
5. Over-reliance on investigations—clinical history is paramount, especially for RLS where no objective test exists 7, 4
6. Prescribing sleep restriction to high-risk occupations—contraindicated in drivers and machinery operators 2